DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus®DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus®DehydraTECH-GLP-1 s ...

"We are extremely encouraged by the interim results received to date aligned with our primary study endpoint," said Richard Christopher, CEO of Lexaria. "DehydraTECH is continuing to demonstrate ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the ...

The Phase 2b Maintenance Extension clinical trial demonstrated that in 12 weeks after stopping semaglutide, the placebo monotherapy group regained 43% of body weight that was previously lost during ...

The enobosarm plus semaglutide followed by enobosarm monotherapy patients had a 58% greater loss of fat with enobosarm 3mg (p=0.085) and a 93% greater loss of fat with enobosarm 6mg (p=0.008 ...

--During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY ...

Phase 2b QUALITY and Maintenance Extension clinical study design After completing the efficacy dose-finding portion of the Phase 2b QUALITY clinical trial, 148 participants continued to the Phase 2b ...

An analysis of 1.7 million patients shows semaglutide may significantly reduce Alzheimer and vascular dementia risk compared with other diabetes drugs.

CHICAGO — The combination of IV bimagrumab and subcutaneous semaglutide was linked to large reductions in body weight and fat mass at 72 weeks with no serious impact on lean mass, according ...

Conclusions Once-weekly cagrilintide–semaglutide (at a dose of 2.4 mg each) resulted in a significantly lower body weight than placebo in adults with obesity and type 2 diabetes.